Eli Lilly unveils data from 57 clinical oncology studies
Pharmaceutical giant Eli Lilly unveiled data from 57 studies from June 4-8 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Two of the studies for which the research results were presented were Phase II studies on Alimta, a chemotherapy drug that has been approved by the Food and Drug Administration (FDA) for the treatment of mesothelioma. These two studies were evaluating the use of Alimta plus platinum-based chemotherapy treatments (carboplatin or cisplatin) in combination with concurrent radiotherapy in advanced non-small cell lung cancer (NSCLC) patients.
For the full story, go to PharmaLive.
